AseptiQuik X Inserts AQX44024
1-1/2 Sanitary AseptiQuik X Insert
AseptiQuik® X large format 1" connectors provide quick and easy sterile connections for high flow applications, even in non-sterile environments. AseptiQuik X's “TWIST-PULL-TWIST” design enables users to quickly transfer large volumes of media easily with less risk of operator error. The connector's robust design provides reliable performance without the need for clamps, fixtures or tube welders. Biopharmaceutical manufacturers can now make 1” sterile connections with the quality and market availability they expect from the leader in single-use connection technology.
Polycarbonate, USP Class VI, ADCF
Up to 60 psi, 4.1 bar
White with blue pull tab
39ºF - 104ºF (4ºC - 40ºC)
Silicone, platinum-cured, USP Class VI, ADCF
At Liquidyne, we prioritize our commitment to quality and consistency. In 2017 we achieved ISO 9001:2015 Quality Management System certification to ensure we can repeatedly deliver consistently high-quality products and solutions. Being an ISO 9001 facility, together with our USP Class VI Testing, ASME Bioprocessing Equipment (BPE), and EHEDG certification guarantee, we have the methodologies to assure quality. We will quickly and accurately rectify any issues if any of our products are ever in non-conformance.
"Thanks so much! What a quick turn around. It is a pleasure working with Liquidyne."
Process Development Manager
"I received the cart yesterday, thanks for the fast delivery! It feels sturdy. I sat on it. It does not bounce. It is also easy to clean and wipe or wash down."
Vice President, Analytical Development and Manufacturing
"Thanks again for reacting so quickly and meeting me halfway with the element. We will be able to get installed and have things keep moving overnight with the night crew. The little things like this are always greatly appreciated when working with Liquidyne."
“This pump cut our processing time from 3 days to 1 shift. I’m not giving this pump back. You will have to come and get it if you want it... and that won’t likely happen.”
VP Antibody Manufacturing